Shearman & Sterling advised the underwriters of Inozyme Pharma’s initial public offering of 8,050,000 shares of common stock at a public offering price of $16 per share, resulting in gross proceeds to the company of approximately $128.8 million. The 8,050,000 shares included 1,050,000 of shares issued pursuant to the underwriters’ option to purchase additional shares. The shares began trading on the Nasdaq Global Select Market under the ticker symbol “INZY” on July 24, 2020.
Bank of Americ, Cowen and Company and Piper Sandler & Co. acted as joint book-running managers for the offering and Wedbush Securities acted as co-manager.
Inozyme Pharma is a rare disease biopharmaceutical company developing novel therapeutics for the treatment of diseases of abnormal mineralization impacting the vasculature, soft tissue and skeleton.
The Shearman & Sterling team below also includes associate Alex Liebmann.